Option chain shows key data for NLS Pharmaceutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NLS Pharmaceutics.

NLS Pharmaceutics (NASDAQ:NLSPW) Stock, Option Chain

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter

Biotech

News

Penny Stocks

General

NLSP

NLS PHARMACEUTICS LTD WT PUR COM SER A EXP

NLSPW

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) recently released a comprehensive shareholder letter by its CEO, Alex Zwyer, detailing recent achievements and ongoing endeavors.

NLS Pharmaceutics Ltd

The Company's net income for 1H 2024 was $44,000 as compared to net loss of $255,000 for 1H 2023 resulting from increase in gross profit.

CLWT

Euro Tech Holdings H1 2024 Revenue $7.259M, Down From $7.957M YoY

Keybanc analyst Eric Heath upgrades Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Sector Weight to Overweight and announces $115 price target.

Upgrades

Price Target

Analyst Ratings

OKTA

Keybanc Upgrades Okta to Overweight, Announces $115 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly in early discussions with officials of the city of Austin, Texas, to roll out its <a href="https://www.benzinga.com/topic/tesla-cybercab">autonomous vehicles for testing</a> as early as 2025.
What Happened: Elon Musk-led Tesla's driverless vehicle ambitions could get a boost if its discussions with Austin City bear fruit.
According to a <a href="https://www.bloomberg.com/news/articles/2024-12-19/tesla-sounds-out-austin-officials-about-long-promised-driverless-fleets">report</a> by Bloomberg, a Tesla employee has been in touch with Austin city officials since as early as May to create a safety framework for deploying driverless fleets.
Reacting to the news, the Tesla stock surged over 3% in premarket trading to hover at $453.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
See Also: <a href="https://www.benzinga.com/tech/24/12/42570564/tesla-says-powerwall-owners-generated-4-5-twh-of-solar-energy-this-year-amid-energy-segment-revenue-boom">Tesla Says Powerwall Owners Generated 4.5 TWh Of Solar Energy This Year Amid Energy Segment Revenue Boom</a>
Why It Matters: Tesla's autonomous driving ambitions have been a key area of focus as analysts determine the impact of a driverless fleet on the EV giant's prospects.
Wedbush analyst Dan Ives and long-time Tesla bull thinks the Tesla stock could hit the <a href="https://www.benzinga.com/24/12/42455654/wedbush-securities-sees-tesla-touching-2-trillion-market-cap-by-2025-end-apple-microsoft-nvidia-to-join-4-trillion-market-cap-club-next-year-says-analyst">$2 trillion market capitalization mark</a> by the end of 2025, in a bull-case scenario.
"We believe with the autonomous story at Tesla worth $1 trillion alone that in a bull case scenario by the end of 2025, Tesla could achieve a $2 trillion market cap threshold," Ives said. "FSD, autonomous, and the launch of Cybercab for early 2026 are keys for Tesla.&#8221;
Tesla has also been <a href="https://www.benzinga.com/tech/24/11/42230503/tesla-cybercab-spotted-testing-in-giga-texas-facility">spotted testing the Cybercab</a> at the Giga Texas facility. A video shared on social media showcased the Cybercab navigating traffic autonomously within the premises.
Price Action: On a year-to-date basis, the stock is up 77.2%. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">Here&#8217;s what other analysts are saying.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571913/tesla-registrations-drop-by-nearly-41-in-november-in-eu-dragging-down-optimism-for-over-500000-ev-deliveries-in-q4">Tesla EU Registrations Plunge 41% In November, Casting Shadow On Q4 Target Of Over 500,000 EV Deliveries</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Tesla

Equities

Markets

Tech

TSLA

Tesla Reportedly In Talks With Austin To Bring Autonomous Vehicles To Texas Roads: Elon Musk-Led EV Giant Rises 3% In Pre Market

Wells Fargo analyst Steven Cahall upgrades Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) from Equal-Weight to Overweight and announces $23 price target.

TGNA

Wells Fargo Upgrades Tegna to Overweight, Announces $23 Price Target

Wells Fargo initiates coverage on Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) with a Equal-Weight rating and announces Price Target of $33.

Initiation

PNTG

Wells Fargo Initiates Coverage On Pennant Gr with Equal-Weight Rating, Announces Price Target of $33

Wells Fargo analyst Derek Archila downgrades Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) from Overweight to Equal-Weight and lowers the price target from $14 to $11.

Downgrades

GLUE

Wells Fargo Downgrades Monte Rosa Therapeutics to Equal-Weight, Lowers Price Target to $11

Conagra Brands Lowers FY25 Outlook: Sees Adjusted EPS Between $2.45-$2.50 Vs. $2.58 Estimate (Prior View: $2.60-$2.65), Projects Organic Net Sales Near The Midpoint Of (1.5)% To Flat YoY

The new facility will accommodate drone manufacturing and assembly, R&amp;D, sales, pilot, and training teams, and has an aeronautical test range site for demonstrations.

ZENA

ZenaTech Subsidiary Moves Into Its Manufacturing Facility In Phoenix, Arizona To Produce US Defense And Nato Drones, Part Of Efforts To Produce 'Made In America' Drones

Contracts

DFLI

Dragonfly Energy Has Secured A Large Purchase Order For Delivery Of The Company's Battle Born All-Electric APUs From Stevens Transport

Deutsche Bank analyst Matt Niknam upgrades Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from Hold to Buy and maintains the price target from $25 to $25.

Deutsche Bank Upgrades Hewlett Packard to Buy, Maintains Price Target to $25

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has rebounded to $102,250 after taking a nosedive on Thursday following <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">the FOMC meeting</a>.
What Happened: Bitcoin cratered from above $105,000 before Thursday&#8217;s trading session to a low of $98,839 during U.S. night time hours. 
It has since rebounded and is down 2.5% over the past 24 hours.
Crypto chart analyst Ali Martinez explained in an X <a href="https://x.com/ali_charts/status/1869520970832138261">post</a> following the Fed meeting that the reaction wasn't due to the 25-bps rate cut, which was largely expected, but rather concerns over persistent inflation and the possibility of prolonged elevated interest rates.
Despite the negative sentiment, Martinez advised traders to &#8220;keep calm, don't panic sell,&#8221; emphasizing that markets dislike uncertainty but typically stabilize once clarity emerges.
Coinglass data reveals that total liquidations in the past 24 hours amounted to $788.5 million, with over 269,623 traders liquidated.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42554929/donald-trump-reportedly-discussed-bitcoin-reserve-in-meeting-with-cryptocom-ceo-kris-marszalek">Donald Trump Reportedly Discussed Bitcoin Reserve In Meeting With Crypto․com CEO Kris Marszalek</a>
Why It Matters: Fed Chair Jerome Powell added to market jitters by calling the decision a "closer call," hinting at divisions within the Federal Reserve. 
This boosted the U.S. Dollar to its highest level since 2022, putting pressure on risk assets like Bitcoin, which experienced a sharp drop.
In a separate tweet, Martinez highlighted funding rates suggesting leveraged positions:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Funding rates look like we should go 100x leverage! &#x1f605; <a href="https://t.co/dLyDhlHI37">pic.twitter.com/dLyDhlHI37</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1869699700162482186?ref_src=twsrc%5Etfw">December 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He also <a href="https://x.com/ali_charts/status/1869651554099499318">noted</a>, &#8220;Binance traders were right; we should have shorted Bitcoin.&#8221; 
Martinez previously noted that 62.6% of Binance traders with open BTC futures positions were going short, aligning with the bearish market sentiment.
Key takeaways from the Fed meeting included the expectation of fewer rate cuts in 2025 (down from three to two), higher inflation forecasts for 2025 (2.5%) and 2026 (2.1%), exceeding the Fed&#8217;s 2% target, and an acknowledgement that inflation metrics like core CPI, core PCE and PPI are ticking up.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42560698/microstrategys-aggressive-bitcoin-strategy-raises-eyebrows-in-crypto-community">MicroStrategy&#8217;s Aggressive Bitcoin Strategy Raises Eyebrows In Crypto Community</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Price Rebounds Above $102,000 After Fed Meeting Calamity: Why Is BTC Going Up?

Health Care

Altimmune Will Be Added To The Nasdaq Biotechnology Index Effective Prior To The Market Open On December 23, 2024

Creedon joined Dollar Tree in 2022 as Chief Operating Officer and over the past two years has taken on increasing levels of responsibility.
In November 2024, Creedon was appointed Interim Chief Executive Officer, succeeding Rick Dreiling. Creedon has responsibility for leading more than 200,000 associates and more than 16,000 stores across the Dollar Tree and Family Dollar banners.

Management

DLTR

Dollar Tree Appoints Interim CEO Michael C. Creedon As Permanent CEO

Wells Fargo analyst Derek Archila downgrades Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) from Overweight to Equal-Weight and announces $27 price target.

VRDN

Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target

Northland Capital Markets analyst Tim Savageaux maintains Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) with a Outperform and raises the price target from $5.5 to $6.

RBBN

Northland Capital Markets Maintains Outperform on Ribbon Comms, Raises Price Target to $6

Needham analyst Ryan MacDonald maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $370 to $385.

DUOL

Needham Maintains Buy on Duolingo, Raises Price Target to $385

All cash offer represents a 58% premium to O3 Mining's closing price on December 11, 2024.&nbsp;
Offer unanimously recommended by Board and Special Committee of O3 Mining and supported by shareholders representing 39% of outstanding shares of O3 Mining.

OIIIF

Agnico Eagle Commences Offer To Acquire All Issued And Outstanding Common Shares Of O3 Mining  For C$1.67 In Cash Per Common Share

<ul>
<li>Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy</li>
<li>Demonstrated efficacy at 6 months
<ul>
<li>71% percent of patients achieved a &gt;30% reduction in the urine protein to&nbsp;creatinine ratio (UP/Cr)</li>
<li>71% of patients achieved improved or stabilized estimated&nbsp;glomerular filtration rate (eGFR)</li>
</ul>
</li>
<li>Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients</li>
</ul>

Palatin Announced Topline Data From BREAKOUT Phase 2b Study Of Bremelanotide In Diabetic Kidney Disease To Assess The Efficacy In Reducing Urinary Protein And Maintaining Podocyte Density And Function

Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.67 by 4.48 percent. The company reported quarterly sales of $3.195 billion which beat the analyst consensus estimate of $3.149 billion by 1.45 percent. This is a 0.41 percent decrease over sales of $3.208 billion the same period last year.

Earnings

Earnings Beats

Conagra Brands Q2 2025 Adj. EPS $0.70 Beats $0.67 Estimate, Sales $3.195B Beat $3.149B Estimate

Northland Capital Markets analyst Tim Savageaux maintains Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) with a Outperform and raises the price target from $9 to $10.

ADTN

Northland Capital Markets Maintains Outperform on Adtran Holdings, Raises Price Target to $10

NLS Pharmaceutics looks to raise $0.79M via securities offering

NLS Pharmaceutics to conduct reverse share split

Press Releases

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

NLS Pharmaceutics Announces Registered Direct Offering

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Offerings

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and  Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Comments

NLS Pharmaceutics

NLS Pharmaceutics (NLSPW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga